J.P. Morgan Reports on Mylan

In a report released today, J.P. Morgan commented on Mylan MYL. In the report, J.P. Morgan was positive in its assessment of the company. J.P. Morgan writes, " With a highly diversified business that we believe is capable of delivering high-teens EPS growth over the next several years, we rate MYL shares Overweight. In addition to a solid US business that is poised for several high-profile launches in 2011 and 2012, we believe Mylan is solidly positioned to take advantage of attractive international opportunities and realize significant cost synergies from its global infrastructure. " J.P. Morgan currently has an Overweight rating on Mylan and a price target of $28. Shares of the company closed the trading day Friday at $23.82, down $0.07 from the opening bell.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareJ.P. MorganPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!